MA
RPRX icon

Menlo Advisors’s Royalty Pharma RPRX Stock Holding History

Menlo Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.12M Sell
126,940
-700
-0.5% -$36.4K 3.12% 13
2026
Q1 		$4.93M Hold
127,640
– – 2.22% 17
2025
Q4 		$4.93M Hold
127,640
– – 2.22% 17
2025
Q3 		$4.5M Sell
127,640
-3,685
-3% -$133K 2.14% 17
2025
Q2 		$4.73M Sell
131,325
-1,910
-1% -$63.3K 2.55% 16
2025
Q1 		$4.15M Hold
133,235
– – 1.97% 18
2024
Q4 		$3.4M Sell
133,235
-14,650
-10% -$388K 1.73% 21
2024
Q3 		$4.18M Hold
147,885
– – 2.15% 18
2024
Q2 		$3.9M Buy
+147,885
New +$4.1M 2.16% 19

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Menlo Advisors's RPRX Position: Q2 2026 in Review

Menlo Advisors reduced its Royalty Pharma (RPRX) stake by 0.55% in Q2 2026, selling an estimated $36.4K and leaving 126,940 shares worth $7.12M. The position accounts for 3.12% of the portfolio, ranked #13.

Menlo Advisors first reported a position in RPRX in Q2 2024 and has held it in 9 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Menlo Advisors held 126,940 shares of Royalty Pharma worth $7.12M as of Q2 2026.
  • Menlo Advisors sold 700 Royalty Pharma shares in Q2 2026, an estimated $36.4K.
  • Royalty Pharma made up 3.12% of Menlo Advisors's portfolio in Q2 2026, its #13 holding.
  • Menlo Advisors first reported a position in Royalty Pharma in Q2 2024 and has held it in 9 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Menlo Advisors's 13F filing for Q2 2026, filed 10 Sep 2026.